Clinical trials: Attention-deficit Hyperactivity Disorder (ADHD)
- Condition Attention-deficit Hyperactivity Disorder (ADHD)
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Disorder With Hyperactivity (ADHD)
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.
- Trial name
- NCT07755410
- Testing
- ALKS 7290
- Where
- 28 sites in United States
- Volunteers
- 312 people
- Sponsor
- Alkermes, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
A Long-term Trial of EB-1020 in Adult Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
- Trial name
- NCT06926829
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Hyperactivity Disorder (ADHD)
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.
- Trial name
- NCT06931080
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 630 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
ADHD
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to <12 years with ADHD.
- Trial name
- NCT07717879
- Testing
- Solriamfetol Dose A, Solriamfetol Dose B
- Where
- 30 sites in United States
- Volunteers
- 468 people
- Sponsor
- Axsome Therapeutics, Inc.
ADHD
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.
- Trial name
- NCT07717892
- Testing
- Solriamfetol Dose A, Solriamfetol Dose B
- Where
- 28 sites in United States
- Volunteers
- 468 people
- Sponsor
- Axsome Therapeutics, Inc.
ADHD
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
This study is a Phase 3, multi-center, open-label trial to evaluate the long-term safety of solriamfetol in children and adolescents with ADHD.
- Trial name
- NCT07773883
- Testing
- Solriamfetol
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Axsome Therapeutics, Inc.
ADHD, Gastrointestinal
ADHD, Gut Problems and Synbiotic
The scope of this study is to evaluate the impact of a synbiotic product (a combination of probiotic bacteria and prebiotics) on symptoms reported by participants with ADHD.
- Conditions
- ADHD, Gastrointestinal, Emotion Regulation Abilities
- Trial name
- NCT07717359
- Testing
- Synbiotic Cap Gut-Brain
- Volunteers
- 174 people
- Sponsor
- Super Synbiotics AB
Attention Deficit Hyperactivity Disorder (ADHD)
Effects of Probiotics on the Gut-brain Axis in Children
The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.
- Trial name
- NCT07459699
- Testing
- Probiotics
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Probi AB
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05631626
- Testing
- CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder
A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean…
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder, ADHD
- Trial name
- AK-D101_BS (NCT07678827)
- Testing
- AK-D101
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Alvogen Korea
ADHD
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with…
- Trial name
- NCT06359899
- Testing
- AK0901 capsule
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Adult ADHD
Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
This was a Phase 2 exploratory study to evaluate the efficacy and safety of EB-1020 SR (centanafadine sustained release [CTN SR]) in treating participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth…
- Trial name
- NCT01939353
- Testing
- CTN SR
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
The current study will investigate if QbMobile can be used to improve the accuracy and objective identification of reduced ADHD symptoms in tests scores once treatment has been initiated.
- Trial name
- NCT07217977
- Testing
- observational study
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Qbtech AB
No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD)
An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinical setting as well as…
- Conditions
- No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
- Trial name
- NCT07220330
- Testing
- QbMobile
- Where
- 3 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Qbtech AB
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05924594
- Testing
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
ADHD
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
- Trial name
- NCT07314333
- Testing
- Centanafadine, Methylphenidate, Lisdexamfetamine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD, Attention Deficit Disorder
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
- Trial name
- NCT05200936
- Testing
- MM120
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 53 people
- Sponsor
- Definium Therapeutics US, Inc.
ADHD
tRNS Treatment for ADHD Symptoms
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD.
- Trial name
- NCT06189703
- Testing
- tRNS
- Where
- 5 sites in United States, Israel
- Volunteers
- 146 people
- Sponsor
- Innosphere